Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Celularity Inc(CELU)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CELU
11/04/2026: CELU (1-star) is currently NOT-A-BUY. Pass it for now.
Celularity is a clinical-stage biotechnology company that specializes in developing off-the-shelf cell therapies derived from placental tissue. The company differentiates itself through a scalable manufacturing model and a portfolio of biomaterial products that generate current revenue. While its placental technology is innovative, the company faces high execution and financial risks common to developmental-stage biotech firms. It is best suited for growth-oriented investors who understand the high volatility of clinical trials and the long-term nature of biotech development. Key developments to monitor include upcoming clinical trial results, the company's ability to secure non-dilutive funding, and continued revenue growth in its biomaterial segment.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-growth potential in cell therapy, but success is highly uncertain due to clinical-stage risks. |
| Momentum investor | Weak fit | The stock has generally lacked sustained upward momentum, making it a poor candidate unless a major positive catalyst occurs. |
| Value investor | Weak fit | As a loss-making biotech firm without stable earnings, it does not meet traditional value investing criteria. |
| Dividend investor | Weak fit | The company does not pay dividends and requires all cash for its operations. |
| Low-risk investor | Weak fit | High volatility and the risk of clinical failure make this stock unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks often experience extreme price swings based on trial results and regulatory updates. |
| Valuation risk | Medium / high | Determining fair value is difficult given the lack of consistent earnings and reliance on long-term clinical potential. |
| Competition risk (Cell Therapy & Biomaterials) | High | The company competes with much larger firms that have greater resources for R&D and market distribution. |
| Business quality | Medium | While the technology is innovative, the company is still in the process of proving its commercial viability. |
| Dividend income | Low / none | Investors should not expect income from this equity investment. |
| Execution risk | High | Success depends on complex clinical trials and scaling manufacturing processes which are difficult to execute. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 2.97% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/04/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.51M USD | Price to earnings Ratio - | 1Y Target Price 2.5 |
Price to earnings Ratio - | 1Y Target Price 2.5 | ||
Volume (30-day avg) 166.4K shares | Beta 0.88 | 52 Weeks Range 0.56 - 2.55 | Updated Date 11/04/2026 |
52 Weeks Range 0.56 - 2.55 | Updated Date 11/04/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.66 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biomaterials Sales | Wound care and surgical products like Biovance and Interfyl. | The company currently generates its only tangible revenue through selling specialized wound-healing products to healthcare providers. |
| Cell Therapy R&D | Pipeline of NK and T-cell clinical trials. | This is a future-focused area; it does not generate current revenue but is the primary driver of the stock's long-term valuation. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 61.48M | Price to Sales(TTM) 1.42 |
Enterprise Value 61.48M | Price to Sales(TTM) 1.42 | ||
Enterprise Value to Revenue 3.29 | Enterprise Value to EBITDA -36.78 | Shares Outstanding 32.45M | Shares Floating 21.96M |
Shares Outstanding 32.45M | Shares Floating 21.96M | ||
Percent Insiders 33.27 | Percent Institutions 11.51 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.